Personal Services Agreement By and Between Stephan R. Targan, MD and Prometheus Laboratories Inc.Prometheus Laboratories Inc • March 20th, 2008 • Pharmaceutical preparations • California
This Agreement (the "Agreement") is effective as of the 1st day of June, 2007 (the "Effective Date") by and between Stephan R. Targan, M.D. with offices at 240 22nd Street, Santa Monica, CA 90402 (hereinafter referred to as the "Consultant"), and Prometheus Laboratories Inc., with offices at 9410 Carroll Park Drive, San Diego, CA 92121-5201 (hereinafter referred to as "Company" or "Prometheus").
SUPPLY AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION d/b/a GlaxoSmithKline AND PROMETHEUS LABORATORIES INC. DATED AS OF October 31, 2007Supply Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations • New York
THIS SUPPLY AGREEMENT (this "Agreement") is made and entered into as of the 31st day of October, 2007 by and between SMITHKLINE BEECHAM CORPORATION, a Pennsylvania corporation doing business as GlaxoSmithKline ("GSK"), and PROMETHEUS LABORATORIES INC., a California corporation ("Prometheus"). GSK and Prometheus are sometimes referred to herein individually as a "Party" and collectively as "Parties."
DISTRIBUTION AGREEMENT by and between AstraZeneca LP and Prometheus Laboratories Inc. DATE: November 19, 2004Distribution Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations • Delaware
This Distribution Agreement (the "Agreement") is made effective as of the 19th day of November, 2004 (the "Effective Date") by and between:
ASSET PURCHASE AND SALE AGREEMENT Between SMITHKLINE BEECHAM CORPORATION d/b/a GLAXOSMITHKLINE and GLAXO GROUP LIMITED as Seller and PROMETHEUS LABORATORIES INC. as Purchaser Dated as of October 31, 2007Asset Purchase and Sale Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations • New York
THIS DISTRIBUTION, SUPPLY AND TRANSITION AGREEMENT (this "Agreement") is entered into as of the 31th day of October, 2007 (the "Execution Date"), by and between Prometheus Laboratories Inc., a corporation organized under the laws of California, having a place of business at 9410 Carroll Park Drive, San Diego, CA 92121 ("Prometheus") and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation, with its principal place of business at One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19101 ("GSK"). Prometheus and GSK are sometimes collectively referred to herein as the "Parties" and separately as a "Party."
Exclusive License Agreement Between The Regents of the University of California and Prometheus Laboratories, Inc.Prometheus Laboratories Inc • March 20th, 2008 • Pharmaceutical preparations • California
This license agreement ("Agreement") is effective this 1st day of December, 1999 (the "Effective Date"), by and between The Regents of the University of California ("The Regents"), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 405 Hilgard Avenue, Los Angeles, California 90095-1406 and Prometheus Laboratories, Inc. ("Prometheus"), a California corporation, having a principal place of business at 5739 Pacific Center Boulevard, San Diego, California 92121.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations • California
The following additional information or material in the Field of Use which is described in the UCLA Patent Rights conceived and reduced to practice prior to the Effective Date in the conduct of the inflammatory bowel disease programs at UCLA under the direction of Braun as the principal investigator:
SETTLEMENT AGREEMENT AND MUTUAL RELEASE AND LICENSE AMENDMENTPrometheus Laboratories Inc • March 20th, 2008 • Pharmaceutical preparations
This Settlement Agreement and Mutual Release and License Amendment (hereinafter referred to collectively as the "Agreement") is effective as of the 30th day of June, 2006 by and among PROMETHEUS LABORATORIES INC., a California corporation ("Prometheus"), CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("Cedars-Sinai") and the REGENTS OF THE UNIVERSITY OF CALIFORNIA ("UCLA") acting through its campus at Los Angeles.
EXCLUSIVE LICENSE AGREEMENT IBD FLAGELLUM DIAGNOSTICSExclusive License Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (together with the exhibits hereto, this "Agreement") is made and entered into effective as of March 29, 2004, by and among Corixa Corporation, a Delaware corporation with its principal place of business located at 1124 Columbia Street, Suite 200, Seattle, Washington 98104 ("Corixa") and Prometheus Laboratories Inc., with its principal place of business located at 5739 Pacific Center Bl., San Diego, California 92121 ("Prometheus"). Each of Corixa and Prometheus may be referred to herein as a "Party" and together as the "Parties."
LICENSE AGREEMENT by and between PROMETHEUS LABORATORIES INC. and ALIZYME THERAPEUTICS LIMITED November 29, 2007License Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT ("Agreement") is effective as of November 29, 2007 (the "Effective Date"), and is by and between PROMETHEUS LABORATORIES INC., a California corporation having its principal place of business at 9410 Carroll Park Drive, San Diego, CA 92121 USA ("Prometheus") and ALIZYME THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales, having its principal place of business at Granta Park, Great Abington, Cambridge, CB21 6GX, United Kingdom ("Alizyme") and, for purposes of Section 13.15 (and any Sections cross-referenced therein) only, Alizyme plc, a corporation organized under the laws of England and Wales and having its registered office at Granta Park, Great Abington, Cambridge, CB21 6GX, United Kingdom ("Alizyme plc").
QuickLinks -- Click here to rapidly navigate through this documentDistribution Agreement • March 20th, 2008 • Prometheus Laboratories Inc • Pharmaceutical preparations
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
